FDA Clearance Tracker · DEN180069
ZIKV Detect 2.0 IgM Capture ELISA
Last checked: Nov 20, 2026Latest source record: May 23, 2019 (this decision)Source: openFDAMethods & limitations
Decided
May 23, 2019
De Novo granted
Time to decision
148 days
Received Dec 26, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN180069
- Device name
- ZIKV Detect 2.0 IgM Capture ELISA
- Applicant
- InBios International, Inc.
- Applicant location
- Seattle, WA
- Received
- Dec 26, 2018
- Decided
- May 23, 2019
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device type
- Zika Virus Serological Reagents (QFO)
- Device class
- Class II
- Regulation
- 21 CFR 866.3935
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for DEN180069
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for InBios International, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K251595 · Decided Oct 12, 2025 · 138 days after receipt
Device type: Over-The-Counter Covid-19 Antigen Test (QYT) · Laboratory Medicine & Pathology
K233358 · Decided Aug 23, 2024 · 329 days after receipt
Device type: Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings (QVF) · Laboratory Medicine & Pathology
- Active Anthrax DetectTM Plus Rapid TestNew device typeDe Novo
DEN220044 · Decided Feb 3, 2023 · 210 days after receipt
Device type: Simple In Vitro Diagnostic Device For The Detection Of Secreted Proteins From Bacillus Spp. In Human Clinical Samples (QUU) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.